Receptos, Inc. and Ono Pharmaceuticals have expanded their collaboration to include the transfer of Receptos’ G-protein-coupled receptor (GPCR) technology platform to Ono. The GPCR platform is a high-resolution protein crystal structure determination technology designed to enable rational drug design for the GPCR therapeutic target class.   Ono will have a non-exclusive sublicense to intellectual property relating to the technology. Receptos will also conduct a program to transfer technology to ...